Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has taken a significant step toward expanding its oncology pipeline by entering into a non-binding letter of intent (LOI) with Ifowonco Informatics Incorporated. The LOI is an initial step toward negotiating a definitive agreement that, if completed, would grant Onco an exclusive option relating to Ifowonco’s proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 (LAG-3). This move signals Onco’s strategic intent to integrate cutting-edge immunotherapy with its existing expertise in DNA damage response (DDR) therapeutics.
The proposed collaboration is designed to combine Ifowonco’s oral small-molecule immune checkpoint technology with Onco-Innovations’ capabilities in DDR therapeutics, translational oncology, and clinical development. The companies believe that the combination of DDR inhibition and LAG-3 blockade could potentially enhance anti-tumour immune responses across multiple solid tumour indications. This synergy is particularly promising because DDR inhibitors have been shown to increase the immunogenicity of tumors, potentially making them more susceptible to checkpoint blockade. If successful, this combination could offer a new treatment paradigm for patients with solid tumors who do not respond to existing immunotherapies.
Ifowonco’s program focuses on developing orally available small-molecule LAG-3 inhibitors, which differ from currently approved LAG-3 therapies that are administered intravenously as monoclonal antibodies. Oral small-molecule inhibitors offer potential advantages in terms of patient convenience, dosing flexibility, and the ability to penetrate tissues more effectively. The companies intend to evaluate the LAG-3 program independently and, where supported by preclinical findings, explore its potential use alongside DDR-based therapeutic approaches, including Onco-Innovations’ ONC010 program. This integrated approach could lead to more personalized and effective cancer treatments.
Thomas O’Shaughnessy, CEO of Onco-Innovations, expressed optimism about the potential agreement, stating that it could position the company “at the intersection of precision oncology and next-generation cancer immunotherapy.” This strategic alignment is critical as the field moves toward combination therapies that target multiple pathways to overcome resistance and improve patient outcomes.
The LAG-3 inhibitor market is poised for growth, with the first LAG-3 monoclonal antibody receiving FDA approval in 2022. However, the development of oral small-molecule inhibitors is still in early stages, and Onco-Innovations is positioning itself to be a leader in this niche. By securing exclusive rights to Ifowonco’s program, Onco could gain a competitive edge in the rapidly evolving immuno-oncology landscape.
For more information on this announcement, the full press release is available at https://ibn.fm/E63Ne. Investors are encouraged to review the latest news and updates regarding ONNVF in the company’s newsroom at https://ibn.fm/ONNVF.
